Alnylam Pharma (ALNY) Received its Third Buy in a Row
After Cantor Fitzgerald and BMO Capital gave Alnylam Pharma (NASDAQ: ALNY) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Alan Carr maintained a Buy rating on Alnylam Pharma today and set a price target of $135. The company’s shares closed on Friday at $89.81.
According to TipRanks.com, Carr is a 4-star analyst with an average return of 5.5% and a 45.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $122.91, a 36.9% upside from current levels. In a report issued on April 8, BMO Capital also maintained a Buy rating on the stock with a $119 price target.
See today’s analyst top recommended stocks >>
Based on Alnylam Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $211 million. In comparison, last year the company had a GAAP net loss of $141 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.